Login to Your Account

Isis Hands Off Respiratory Portfolio To Start-Up Altair

By Jennifer Boggs

Wednesday, October 17, 2007
A month after sealing a joint venture deal focused on microRNA, Isis Pharmaceuticals Inc. continues to capitalize on its growing antisense platform by licensing rights to an inhaled asthma product to newly formed Altair Therapeutics Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription